PresentationsNX-1607, a small molecule inhibitor of CBL-B, enhances anti-PD-1-mediated tumor growth inhibition by reshaping intratumoral innate and adaptive immune responses By AldenMC Production / November 1, 2023
PresentationsOvercoming Acquired Inhibitor Resistance & Addressing Novel Scaffolding Functions of BTK in the Clinic By AldenMC Production / October 31, 2023
PresentationsNX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders By AldenMC Production / October 6, 2023
PresentationsTargeting a Novel E3 Ligase with a Small Molecule Inhibitor By AldenMC Production / September 27, 2023
PresentationsTargeted Protein Degradation of BTK Overcomes Clinically-Relevant Resistance Mutations and Its Oncogenic Scaffolding Functions By AldenMC Production / September 26, 2023
PresentationsNX-1607, a small molecule inhibitor of CBL-B, is efficacious as a single agent and in combination with Rituximab in preclinical mouse models of lymphoma By AldenMC Production / September 25, 2023
PresentationsTargeted Protein Degraders for the Treatment of Hematologic Malignancies: Addressing the Mutational Resistance of BTK in the Clinic By AldenMC Production / September 20, 2023
PresentationsFirst Disclosure of NX-5948, an Oral Targeted Degrader of Bruton’s Tyrosine Kinase (BTK) for the Treatment of B-cell Malignancies By AldenMC Production / August 16, 2023
PresentationsTargeted Protein Degradation for Treatment of Hematologic Malignancies Addressing Both the Enzymatic and Scaffolding Functions of BTK Using NX-5948 and NX-2127 in the Clinic By AldenMC Production / July 26, 2023
